Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Cancers acquire resistance to immunotherapy by eliminating tumor-specific genetic mutations

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

6 Jan 2017

Delayed chemotherapy after surgery may benefit lung cancer patients, new Yale study suggests

A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.

6 Jan 2017

NSCLC patients treated with surgery may benefit from delayed chemotherapy, study shows

A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new study published online by JAMA Oncology.

5 Jan 2017

Fred Hutch’s new Evergreen Fund to promote commercialization of research into lifesaving therapies

Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.

28 Dec 2016

Study reveals impact of histology on SBRT treatment in early-stage NSCLC patients

Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.

23 Dec 2016

Breast cancer patient finds new hope with potentially revolutionary treatment

City of Hope patient Susan Young has had a remarkable response to a potentially revolutionary new treatment, a combination of the p53 cancer vaccine and a drug that blocks a specific cancer-aiding protein.

21 Dec 2016

PD-1 protein could serve as biomarker for predicting survival of lung cancer patients

The biomarker PD-1, a protein, could potentially be used to predict survival or disease-free survival of lung cancer patients who have had the tumour surgically removed.

6 Dec 2016

Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016.

23 Nov 2016

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Pembrolizumab was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen.

22 Nov 2016

Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

Immunotherapy continues to revolutionize the field of non-small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.

18 Nov 2016

HC-based NGS helps detect genomic alterations not identified in routine lung cancer screening

The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.

17 Nov 2016

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).

16 Nov 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).

25 Oct 2016

Identification of new lung cancer subtypes could lead to personalized immunotherapies

Personalized therapies can potentially improve the outcomes of patients with lung cancer, but how to best design such an approach is not always clear.

24 Oct 2016

HIIT program effective in improving aerobic performances in early-stage operable NSCLC patients

Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.

20 Oct 2016

Blood tests may decrease wait time between diagnosis and treatment of lung cancer

A study from Gundersen Health System, La Crosse, Wisconsin, reveals to the value of blood-based genomic and proteomic testing in patients with lung cancer at the time of initial diagnoses.

18 Oct 2016

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.

7 Oct 2016

Single high-intensity SBRT dose can be effective in treating early stage NSCLC patients

Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of delivering radiotherapy, or radiation therapy, to treat cancer.

28 Sep 2016

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment.